David Hering, Invivyd CEO

In­vivyd scores EUA for Covid-19 pre­ven­tion drug Pem­gar­da

The FDA gave the green light to In­vivyd’s Pem­gar­da for Covid-19 pre­ven­tion in high-risk im­muno­com­pro­mised pa­tients, is­su­ing an emer­gency use au­tho­riza­tion on Fri­day for the mon­o­clon­al an­ti­body.

The drug is ap­proved for pa­tients 12 years and old­er who are un­like­ly to de­vel­op an ad­e­quate im­mune re­sponse from vac­ci­na­tion, aren’t cur­rent­ly in­fect­ed with the virus or have been re­cent­ly ex­posed to Covid-19.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.